Biopsy-to-biomarker results still take 27 days for lung cancer, according to study
“Even as biomarker testing has become increasingly important for selecting the right lung cancer treatment, the time it takes to order these tests hasn’t improved. Overall, the time from biopsy to biomarker results is about twice as long as most doctors think it is, and that wait can affect whether patients get started on the correct first-line treatment to match their cancer, such as targeted therapy or immunotherapy.”
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
“The potential first-in-class ADC failed to significantly improve overall survival (OS) compared with docetaxel chemotherapy in patients with previously treated nonsquamous NSCLC, causing the phase 3 SigVie-002 trial, also known as Be6A Lung-01, to miss its primary endpoint.”
IMforte Trial Results and Efficacy Data
“Dr. Chiang presents the IMforte trial results, representing the first positive maintenance study in SCLC with both progression-free survival (PFS) and overall survival (OS) benefits. Patients completing induction chemotherapy with atezolizumab were randomized to lurbinectedin plus atezolizumab versus atezolizumab alone, demonstrating OS improvement from approximately 10 to 13 months, representing a 3-month benefit.”
Biomass burning, PM2.5 peaks, and trends in lung adenocarcinoma diagnoses: an ecological study in São Paulo State, Brazil
“Lung adenocarcinoma diagnoses have increased globally despite declining tobacco exposure, raising questions about non–tobacco-related contributors. The role of fine particulate matter (PM2.5) peaks related to biomass burning in shaping population-level lung cancer patterns remains unexplored.”
Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLC
“The therapy demonstrated strong antitumor activity and high rates of tumor shrinkage across both major disease histologies and all biomarker expression levels. Furthermore, the treatment regimen exhibited a manageable safety profile with minimal severe side effects, supporting its continued evaluation in an ongoing large-scale phase three clinical trial.”
Safety and efficacy results of the Phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutations
“Silevertinib is a brain-penetrant therapeutic option designed to target a wide range of non-classical EGFR mutations in non-small cell lung cancer. In its Phase 2 evaluation for first-line treatment, the drug demonstrated meaningful systemic tumor reduction and notable central nervous system activity for individuals presenting with brain metastases.”
Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
“After publication, concerns were raised about substantial changes made to the study registration on (NCT05549037). Key elements, including endpoints, eligibility criteria, sample size, and study design, appear to have been inconsistently reported and modified over time.”
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Advanced NSCLC
“Key Takeaways: FDA fast track designation targets a high-unmet-need, post-platinum/post–PD-(L)1 KRAS G12D–mutant NSCLC population with no approved mutation-specific therapies. VS-7375 inhibits KRAS G12D in both GTP-bound “ON” and GDP-bound “OFF” states, differentiating it from investigational agents predominantly targeting a single conformer.”
Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC
“Dr. Benjamin Levy introduces an expert panel to discuss the increasingly complex landscape of EGFR-mutant advanced non-small cell lung cancer (NSCLC) treatment. The frontline setting now includes three viable options representing a significant shift from the previously straightforward osimertinib monotherapy approach.”
Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma
“Conclusions: Distinct TAAb panels were identified for SCLC and LUAD, serving as accurate diagnostic markers that enable early detection and as indicators of prognosis in different clinical contexts.”
New alliance study tests immunotherapy to prevent lung cancer recurrence
“The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Alliance A082302 aims to enroll 336 participants in this phase III trial specifically focusing on patients with stage I non-small cell lung cancer.”
Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer
“Two investigational KRAS inhibitors showed activity in previously treated KRAS-mutant non–small cell lung cancer (NSCLC), according to findings presented during the Clinical Trials Plenary Session at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. Elisrasib was evaluated in KRAS G12C–mutated NSCLC, including patients previously treated with a KRAS G12C inhibitor, whereas zoldonrasib was studied in KRAS G12D–mutated NSCLC, a subset with no approved RAS-targeted therapy.”
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
“Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy with or without pembrolizumab in patients with advanced RET fusion-positive non-small cell lung cancer.”
Biological aging and generational shifts in early-onset cancer risk
“Incidence of early-onset cancer is rising globally in recent generations, which underscores the need to elucidate the influence of emerging generational risk factors. Systemic and organ-specific aging reflects the cumulative impact of exposures and may provide an integrative and complementary approach to understand early-onset cancer risk.”
LETTER | Tell EPA to Protect Public Health from Toxic PFAS in Drinking Water
“The safety of drinking water is at risk. The Environmental Protection Agency (EPA) has proposed to eliminate legally enforceable limits for four PFAS found in drinking water and delay the enforcement of limits on two more PFAS.”
